About
Technology
Issues
FAQ
Links
Official Page
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.